Genetic, Developmental & Paediatric Neurological Disorders:
From Birth to Adulthood, When the Nervous System's Blueprint Needs Expert Reading

The first assessment for a suspected genetic neurological condition at KIMS covers three things: (1) A clinical examination by a specialist who is specifically familiar with the condition — not a generic neurology examination. Different genetic conditions have very specific clinical signatures (the café-au-lait spots of NF1, the cerebellar signs of Friedreich's Ataxia, the warm-up phenomenon of Myotonia Congenita) that must be specifically sought. (2) The appropriate genetic test — not all genetic conditions require the same test. Some require repeat sizing (Friedreich's Ataxia, SCAs), some require gene panels (CMT, HSP), some require chromosomal analysis (Klinefelter). KIMS orders the right test for the clinical picture, not a generic panel. (3) A structured multi-system baseline — because most genetic neurological conditions affect more than just the nervous system. Cardiac assessment in Friedreich's Ataxia and NF1, renal assessment in TSC and VHL, ophthalmology in NF1 and NF2, hearing in NF2 and some SCAs. Call 040-44885000 to arrange the KIMS assessment.

In most cases, the underlying genetic defect cannot currently be corrected — gene therapy for genetic neurological conditions is an active research area but is not yet standard clinical care for most conditions in this section. However, "no cure" does not mean "no treatment." Each condition in this section has specific evidence-based management that meaningfully changes the course of the condition: mTOR inhibitors (everolimus) reduce SEGA growth and seizure frequency in Tuberous Sclerosis; botulinum toxin and surgery improve function in Cerebral Palsy; bevacizumab preserves hearing in NF2; omaveloxolone was approved for Friedreich's Ataxia in 2023; mTOR inhibitors are also used in VHL. The goal of KIMS management is maximum function, minimum complication, and the longest possible period of independence and quality of life. Call 040-44885000.

Yes — for most autosomal dominant conditions (NF1, NF2, SCA, HSP type SPG4, VHL, TSC, Friedreich's Ataxia in families where the genotype is known), predictive genetic testing of at-risk first-degree relatives is strongly recommended at KIMS. The reason is not just academic: identifying a person who carries the gene before symptoms develop allows surveillance to begin earlier — and for conditions like VHL and NF2, early tumour detection changes outcomes significantly. For autosomal recessive conditions, carrier testing of siblings is recommended to inform their reproductive planning. KIMS arranges cascade testing and genetic counselling for the entire family at the time of the index diagnosis. Call 040-44885000.

At KIMS, pre-conception genetic counselling for couples where one or both partners carry a genetic neurological condition covers three areas. First, the specific recurrence risk for your condition — 50% for autosomal dominant conditions (NF1, NF2, VHL, SCAs, HSP SPG4), 25% for autosomal recessive conditions when both parents are carriers (Friedreich's Ataxia, CMT4, recessive HSP). Second, prenatal diagnosis options: chorionic villus sampling (CVS) at 11–13 weeks of pregnancy to test the fetus directly for the specific mutation. Third, pre-implantation genetic diagnosis (PGD) via IVF: embryos are tested before transfer, allowing selection of unaffected embryos. All options are discussed openly without pressure at KIMS. Call 040-44885000.

Cerebral Palsy (CP) is caused by brain injury around the time of birth — it is not typically a heritable genetic condition. The brain injury produces a static (non-progressive) motor impairment that manifests as spasticity, movement difficulties, and sometimes seizures and intellectual disability. The cause of the injury (birth asphyxia, prematurity, neonatal jaundice) is usually identifiable and is not passed on to future children. Genetic neurological disorders, by contrast, arise from inherited gene mutations or chromosomal variations that may recur in future pregnancies and may affect other family members. However, some cases of CP can be associated with underlying genetic conditions — which is why a genetic assessment is recommended at KIMS for children with CP who have no clear birth history cause, or who have a family history of similar conditions. Call 040-44885000.

Yes — Autism Spectrum Disorder is a neurodevelopmental condition arising from differences in how the brain develops and processes information. It is neurological in origin, with strong genetic contributions (twin studies show heritability of approximately 80–90%). At KIMS Neuroscience, the neurological assessment of a child with ASD covers: ruling out specific genetic syndromes that present with autistic features (Tuberous Sclerosis, Fragile X, Angelman syndrome, Phelan-McDermid syndrome), EEG assessment where seizures are suspected, and neuropsychological assessment of the specific cognitive and sensory profile. The diagnosis of ASD is not a dead end — it is the starting point for a structured support plan. Call 040-44885000.

Yes — direct neurology and clinical-genetics appointments are accepted for all conditions covered here. Outpatient: 040-44885000 (Mon–Sat). If you have previous MRI films, EEGs, genetic test results, or developmental assessments, please bring them — the first KIMS assessment is much more efficient if the prior workup is in hand. For drug-resistant seizures in a known TSC or genetic patient, or acute neurological deterioration, call 040-46324365 immediately.